Kela Ram, Davies Melanie J
Consultant Diabetes, Doncaster and Bassetlaw Hospitals NHS Trust, Bassetlaw Hospital, Worksop, UK.
Expert Opin Biol Ther. 2012 Nov;12(11):1551-6. doi: 10.1517/14712598.2012.716823. Epub 2012 Aug 16.
Liraglutide is a Glucagon like Peptide-1 (GLP-1) receptor agonist, which stimulates GLP-1 receptors and consequently leads to various cardio-metabolic and glycemic improvements in individuals with Type 2 Diabetes Mellitus (T2DM). It is administered once daily as a subcutaneous injection and has been extensively studied in randomized placebo and active comparator studies demonstrating favorable effects on glycemic control and weight reduction. This short review summarizes the role and practical use of this agent in the context of efficacy and safety information obtained during clinical trials.
利拉鲁肽是一种胰高血糖素样肽-1（GLP-1）受体激动剂，它刺激GLP-1受体，从而在2型糖尿病（T2DM）患者中带来各种心血管代谢和血糖改善。它通过皮下注射每日给药一次，并且在随机安慰剂和活性对照研究中得到了广泛研究，证明对血糖控制和体重减轻有良好效果。这篇简短综述总结了该药物在临床试验期间获得的疗效和安全性信息背景下的作用及实际应用。
